Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander A Vinks

Showing results (111-120 of 196) with videos related to

Pageof 20
Sort By:
Expert Opinion on Drug Metabolism & Toxicology|October 13, 2020
Pharmacotherapy of neonatal opioid withdrawal syndrome: a review of pharmacokinetics and pharmacodynamicsMatthijs W van Hoogdalem, Brooks T McPhail, David Hahn, et al.
Transplantation|April 12, 2012
Risk of tacrolimus toxicity in CYP3A5 nonexpressors treated with intravenous nicardipine after kidney transplantationDavid K Hooper, Tsuyoshi Fukuda, Rhonda Gardiner, et al.
Frontiers in Pharmacology|January 25, 2021
PK/PD Study of Mycophenolate Mofetil in Children With Systemic Lupus Erythematosus to Inform Model-Based Precision DosingYewei Chen, Li Sun, Hong Xu, et al.
The Journal of Antimicrobial Chemotherapy|September 3, 2016
Urinary kidney injury biomarkers and tobramycin clearance among children and young adults with cystic fibrosis: a population pharmacokinetic analysisKevin J Downes, Min Dong, Tsuyoshi Fukuda, et al.
Clinical Therapeutics|October 11, 2011
Pharmacokinetics of prednisolone at steady state in young patients with systemic lupus erythematosus on prednisone therapy: an open-label, single-dose studyAnna Carmela P Sagcal-Gironella, Catherine M T Sherwin, Rommel G Tirona, et al.
Neurology|April 1, 2016
Obesity and overweight as CAE comorbidities and differential drug response modifiersRavindra Arya, Catherine W Gillespie, Avital Cnaan, et al.
Clinical Pharmacokinetics|January 5, 2019
Developmental Pharmacokinetics and Age-Appropriate Dosing Design of Milrinone in Neonates and Infants with Acute Kidney Injury Following Cardiac SurgeryTomoyuki Mizuno, Katja M Gist, Zhiqian Gao, et al.
Therapeutic Drug Monitoring|May 14, 2013
Population pharmacokinetics of sirolimus in pediatric patients with neurofibromatosis type 1Jeffrey R Scott, Joshua D Courter, Shannon N Saldaña, et al.
Clinical Drug Investigation|June 12, 2013
Developmental changes in morphine clearance across the entire paediatric age range are best described by a bodyweight-dependent exponent modelChenguang Wang, Senthilkumar Sadhavisvam, Elke H J Krekels, et al.
Therapeutic Drug Monitoring|September 19, 2023
Ceftriaxone Pharmacokinetics and Pharmacodynamics in 2 Pediatric Patients on Extracorporeal Membrane Oxygenation TherapyFrancisco C Cervantes, Tomoyuki Mizuno, Min Dong, et al.
Pageof 20

Showing results (111-120 of 196) with videos related to

Sort By:
Pageof 20
Expert Opinion on Drug Metabolism & Toxicology|October 13, 2020
Pharmacotherapy of neonatal opioid withdrawal syndrome: a review of pharmacokinetics and pharmacodynamicsMatthijs W van Hoogdalem, Brooks T McPhail, David Hahn, et al.
Transplantation|April 12, 2012
Risk of tacrolimus toxicity in CYP3A5 nonexpressors treated with intravenous nicardipine after kidney transplantationDavid K Hooper, Tsuyoshi Fukuda, Rhonda Gardiner, et al.
Frontiers in Pharmacology|January 25, 2021
PK/PD Study of Mycophenolate Mofetil in Children With Systemic Lupus Erythematosus to Inform Model-Based Precision DosingYewei Chen, Li Sun, Hong Xu, et al.
The Journal of Antimicrobial Chemotherapy|September 3, 2016
Urinary kidney injury biomarkers and tobramycin clearance among children and young adults with cystic fibrosis: a population pharmacokinetic analysisKevin J Downes, Min Dong, Tsuyoshi Fukuda, et al.
Clinical Therapeutics|October 11, 2011
Pharmacokinetics of prednisolone at steady state in young patients with systemic lupus erythematosus on prednisone therapy: an open-label, single-dose studyAnna Carmela P Sagcal-Gironella, Catherine M T Sherwin, Rommel G Tirona, et al.
Neurology|April 1, 2016
Obesity and overweight as CAE comorbidities and differential drug response modifiersRavindra Arya, Catherine W Gillespie, Avital Cnaan, et al.
Clinical Pharmacokinetics|January 5, 2019
Developmental Pharmacokinetics and Age-Appropriate Dosing Design of Milrinone in Neonates and Infants with Acute Kidney Injury Following Cardiac SurgeryTomoyuki Mizuno, Katja M Gist, Zhiqian Gao, et al.
Therapeutic Drug Monitoring|May 14, 2013
Population pharmacokinetics of sirolimus in pediatric patients with neurofibromatosis type 1Jeffrey R Scott, Joshua D Courter, Shannon N Saldaña, et al.
Clinical Drug Investigation|June 12, 2013
Developmental changes in morphine clearance across the entire paediatric age range are best described by a bodyweight-dependent exponent modelChenguang Wang, Senthilkumar Sadhavisvam, Elke H J Krekels, et al.
Therapeutic Drug Monitoring|September 19, 2023
Ceftriaxone Pharmacokinetics and Pharmacodynamics in 2 Pediatric Patients on Extracorporeal Membrane Oxygenation TherapyFrancisco C Cervantes, Tomoyuki Mizuno, Min Dong, et al.
Pageof 20